Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Daré Bioscience, Inc. furnished a current report to let investors know it has posted an updated corporate presentation on its investor relations website. The presentation is dated March 2, 2026 and is also attached as Exhibit 99.1 to the report for convenient access.

The company states that this investor presentation is being furnished under Regulation FD, not filed, which means it is not subject to certain securities law liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. No financial results or new transaction details are described in the excerpt.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

03/02/2026 - 08:01 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2026

DARE BIOSCIENCE, INC.

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36395

20-4139823

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 2, 2026, Daré Bioscience, Inc. (“Daré” or the “Company”) made available an updated corporate presentation in the “Investors” section of its website (https://ir.darebioscience.com). A copy of the presentation, dated March 2, 2026, is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Information contained in, or that can be accessed through, the Company’s website or any other website referenced in its corporate presentation is not incorporated by reference into this report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.		Description
99.1		Daré Bioscience corporate presentation, dated March 2, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DARÉ BIOSCIENCE, INC.

Dated: March 2, 2026	By:	/s/ Sabrina Martucci Johnson
	Name:	Sabrina Martucci Johnson
	Title:	President and Chief Executive Officer

-3-

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Daré Bioscience (DARE) disclose in its latest 8-K filing?

Daré Bioscience disclosed that it made an updated corporate presentation available in the Investors section of its website. The presentation, dated March 2, 2026, is also included as Exhibit 99.1, giving investors a structured overview of company information.

Where can investors access Daré Bioscience’s updated March 2, 2026 presentation?

Investors can access Daré Bioscience’s updated corporate presentation in the Investors section of its website at https://ir.darebioscience.com. The same presentation, dated March 2, 2026, is furnished as Exhibit 99.1 to the company’s current report for reference.

How is Daré Bioscience’s March 2, 2026 investor presentation treated under securities laws?

Daré Bioscience states the presentation is furnished, not filed, under Regulation FD. As a result, it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced by the company.

What exhibits were included with Daré Bioscience’s March 2, 2026 current report?

The current report includes Exhibit 99.1, which is the Daré Bioscience corporate presentation dated March 2, 2026. It also includes Exhibit 104, described as the Cover Page Interactive Data File embedded within the Inline XBRL document used for electronic reporting.

Does Daré Bioscience incorporate website information into this current report?

Daré Bioscience explains that information on its website, or any other site referenced in the corporate presentation, is not incorporated by reference into the current report. Only information expressly incorporated by specific reference would become part of the company’s SEC filings.

Filing Exhibits & Attachments

34 documents

Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K

Rhea-AI Filing Summary

Positive

Negative